Rosuvastatin treatment is associated with a decrease of serum oxidised low-density lipoprotein/beta2-glycoprotein i complex concentration in type 2 diabetes

British Journal of Diabetes and Vascular Disease

Volumn 10, Issue 6, 2010, Pages 292-299

  Ames, Paul Rj ^a   Ortiz Cadenas, Alfredo ^b   Garcia De La Torre, Ignacio ^b   Nava, Arnulfo ^b,c   Oregon Miranda, Aldo ^b   Batuca, Joana R ^d   Kojima, Kazuo ^e   Lopez, Luis R ^f   Matsuura, Eiji ^g  

^a AIREDALE GENERAL HOSPITAL   (United Kingdom)

^b HOSPITAL GENERAL DE OCCIDENTE   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^d UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^e Medical & Biological Laboratories Co Ltd   (Japan)

^f Division of Medicine   (United States)

^g OKAYAMA UNIVERSITY   (Japan)

Author keywords

diabetes; oxidative stress; oxidised low density lipoprotein beta2 glycoprotein I

Indexed keywords

3 NITROTYROSINE; BETA2 GLYCOPROTEIN 1; CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; NITRATE; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; DIABETIC PATIENT; FEMALE; HUMAN; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLITE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79751475968     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/1474651410388057     Document Type: Article

References (43)

1. Giugliano D., Ceriello A., Paolisso G. Oxidative stress and diabetic vascular complications. Diabetes Care 1996 ; 19: 257-67. (Pubitemid 26070354)
2. Nourooz-Zadeh J., Cooper MB, Ziegler D., Betteridge DJ Urinary 8-epi-PGF2alpha and its endogenous beta-oxidation products (2,3-dinor and 2,3-dinor-5,6-dihydro) as biomarkers of total body oxidative stress. Biochem Biophys Res Commun 2005 ; 330: 731-6. (Pubitemid 40462148)
3. Gopaul NK, Anggård EE, Mallet AI et al. Plasma 8-epi-PGF2 alpha levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett 1995 ; 368: 225-9.
4. Davì G, Ciabattoni G, Consoli A. et al. In vivo formation of 8-iso-prostaglandin F2 alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999 ; 99: 224-9. (Pubitemid 29056363)
5. Thomas DD, Ridnour LA, Isenberg JS et al. The chemical biology of nitric oxide: Implications in cellular signalling. Free Radic Biol Med 2008 ; 45: 18-31.
6. Denicola A., Batthyany C., Lissi E. et al. Diffusion of nitric oxide into low-density lipoprotein. J Biol Chem 2002 ; 277: 932-6. (Pubitemid 34968836)
7. Peluffo G., Radi R. Biochemistry of protein tyrosine nitration in cardiovascular pathology. Cardiovasc Res 2007 ; 75: 291-302. (Pubitemid 46961930)
8. Pacher P., Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007 ; 87: 315-24.
9. Cromwell WC, Barringer TA Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease. Curr Cardiol Rep 2009 ; 11: 468-75.
10. Malle E., Marsche G., Arnhold J., Davies MJ Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim Biophys Acta 2006 ; 1761: 392-415. (Pubitemid 43776460)
11. Leeuwenburgh C., Hardy MM, Hazen SL et al. Reactive nitrogen intermediates promote low-density lipoprotein oxidation in human atherosclerotic intima. J Biol Chem 1997 ; 272: 1433-6. (Pubitemid 27043215)
12. Matsuura E., Shen L., Matsunami Y. et al. Pathophysiology of beta2-glycoprotein I in ntiphospholipid syndrome. Lupus 2010 ; 19: 379-84.
13. Kobayashi K., Kishi M., Atsumi T. et al. Circulating oxidized LDL forms complexes with β2-glycoprotein I: implications as an atherogenic auto-antigen. J Lipid Res 2003 ; 44: 716-26. (Pubitemid 37279673)
14. Ames PRJ, Antinolfi I., Ciampa A. et al. Primary antiphospholipid syndrome: a low-grade auto-inflammatory disease? Rheumatology 2008 ; 47: 1832-7.
15. Lopez D., Garcia-Valladares I., Palafox-Sanchez C. et al. Oxidized low-density lipoprotein/β2-glycoprotein I complexes and autoantibodies to oxLig-1/β2-glycoprotein I in patients with systemic lupus erythematosus and antiphospholipid syndrome. Am J Clin Pathol 2004 ; 121: 426-36. (Pubitemid 38298177)
16. Kasahara J., Kobayashi K., Maeshima Y. et al. Clinical significance of serum oxidized low-density lipoprotein/β2-glycoprotein I complexes in patients with chronic renal diseases. Nephron Clin Practice 2004 ; 98: 15-24.
17. Lopez LR, Hurley BL, Simpson DF, Matsuura E. Oxidized low-density lipoprotein/β2-glycoprotein I complexes in type 2 diabetes mellitus. Ann NY Acad Sci 2005 ; 1051: 97-103. (Pubitemid 41362736)
18. Yla-Hertula S., Palinski W., Rosenfeld ME et al. Evidence for the presence of oxidatively modified low-density lipoprotein in atherosclerotic lesion of rabbit and man. J Clin Invest 1989 ; 84: 1086-95. (Pubitemid 19247577)
19. George J., Harats D., Gilburd B. et al. Immunolocalization of β2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 1999 ; 99: 2227-30. (Pubitemid 29201126)
20. Liu Q., Kobayashi K., Furukawa J. et al. ω-Carboxyl variants of 7-ketocholesteryl esters are ligands for β2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. J Lipid Res 2002 ; 43: 1486-95.
21. Matsuura E., Kobayashi K., Inoue K. et al. Oxidized LDL/β2- glycoprotein I complexes: new aspects in atherosclerosis. Lupus 2005 ; 14: 736-41. (Pubitemid 41413302)
22. Tabuchi M., Inoue K., Usui-Kataoka H. et al. The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res 2007 ; 48: 768-81. (Pubitemid 46557882)
23. Undas A., Brummel-Ziedins KE, Mann KG Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005 ; 25: 287-94. (Pubitemid 40189147)
24. Shishehbor MH, Brennan ML, Aviles RJ et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation 2003 ; 108: 426-31. (Pubitemid 36935535)
25. World Health Organisation: Diabetes mellitus: Report of a WHO Study Group. Tech Rep Ser # 727: 1-113. Geneva: World Health Organisation, 1985.
26. Arellano-Montano S., Bastarrachea-Sosa RA, Bourges-Rodriguez H. et al. La obesidad en Mexico. Revista Endocrinologia Nutricion 2004 ; 12 (Suppl 3): S80-7.
27. Eckerson HW, Wyte CM, La Du BN The human serum paraoxonase/ arylesterase polymorphism. Am J Hum Genet 1983 ; 35: 1126-38. (Pubitemid 14201166)
28. Giovannoni G., Land JM, Keir G. et al. Adaptation of the nitrate reductase and Griess reaction methods for the measurement of serum nitrate plus nitrite levels. Ann Clin Biochem 1997 ; 34: 193-8. (Pubitemid 27121044)
29. Song F., Jia W., Yao Y. et al. Oxidative stress, antioxidant status and DNA damage in patients with impaired glucose regulation and newly diagnosed Type 2 diabetes. Clin Sci (Lond) 2007 ; 112: 599-606. (Pubitemid 46849550)
30. Schneider MP, Ritt M., Raff U., Ott C. Gender is related to alterations of renal endothelial function in type 2 diabetes. Nephrol Dial Transplant 2009 ; 24: 3354-9.
31. Liao JK Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002 ; 110: 285-8. (Pubitemid 34847957)
32. Essig M., Nguyen G., Prie D. et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells: role of geranylgeranylation and Rho proteins. Circ Res 1998 ; 83: 683-90. (Pubitemid 28462781)
33. Endres M., Laufs U., Huang Z. et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1998 ; 95: 8880-5. (Pubitemid 28350583)
34. Laufs U., La Fata V., Plutzky J., Liao JK Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998 ; 97: 1129-35. (Pubitemid 28152885)
35. Blake GJ, Ridker PM Are statins anti-inflammatory? Curr Control Trials Cardiovasc Med 2000 ; 1: 161-5. (Pubitemid 32219905)
36. Takemoto M., Liao JK Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001 ; 21: 1712-19. (Pubitemid 34219772)
37. Resch U., Tatzber F., Budinsky A., Sinzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol 2006 ; 61: 262-74. (Pubitemid 43382625)
38. Verreth W., De Keyzer D., Davey PC et al. Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice. Br J Pharmacol 2007 ; 151: 347-55. (Pubitemid 46842672)
39. Grosser N., Erdmann K., Hemmerle A. et al. Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1. Biochem Biophys Res Commun 2004 ; 325: 871-6. (Pubitemid 39487953)
40. Manfredini V., Biancini GB, Vanzin CS et al. Apolipoprotein, C-reactive protein and oxidative stress parameters in dyslipidemic type 2 diabetic patients treated or not with simvastatin. Arch Med Res 2010;41: 104-09.
41. Su Y., Xu Y., Sun YM et al. Comparison of the effects of simvastatin versus atorvastatin on oxidative stress in patients with type 2 diabetes mellitus. J Cardiovasc Pharmacol 2010 ; 55: 21-5.
42. Akalin A., Temiz G., Akcar N., Sensoy B. Short term effects of atorvastatin on endothelial functions and oxidized LDL levels in patients with type 2 diabetes. Endocr J 2008 ; 55: 861-6.
43. Paniagua JA, López-Miranda J., Pérez-Martínez P. et al. Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: a study of endothelial function and microalbuminuria. Diabet Med 2005 ; 22: 1647-56. (Pubitemid 43046463)